Sight SciencesSGHT
Recorded

Sight Sciences 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration54 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and thank you for standing by. Welcome to the Sight Sciences Third Quarter Earnings Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Hannah Jeffrey, Investor Relations.

Hannah JeffreyVP of Investor Relations

Thank you for participating in today's call. Presenting today are Sight Sciences Co-Founder and Chief Executive Officer, Paul Badawi, and Chief Financial Officer, Jim Rodberg. Also in attendance is Sight Sciences Chief Operating Officer, Ali Bauerlein. Earlier today, Sight Sciences released financial results for the third quarter ended September 30, 2026, raised its revenue guidance, and maintained its adjusted operating expense guidance for the full year 2026. A copy of the press release is available on our website at investors.sightsciences.com. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements within the meaning of federal securities laws. These statements are based on plans and expectations as of today, which may change over time. In addition, actual results could differ materially from projected results due to a number of risks and uncertainties.

Hannah JeffreyVP of Investor Relations

For discussion of risks and other factors that may affect the company's future financial results and business, please refer to the earnings release issued prior to this call and the company's SEC filings. We undertake no obligation to publicly update or revise any forward-looking statements except as required by law. Also on this call, management refers to certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S., including adjusted operating expenses. We believe these non-GAAP financial measures are important indicators of the company's operating performance because they exclude items that are unrelated to and may not be indicative of its core operating results. See our earnings release for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, as well as additional information about our reliance on non-GAAP financial measures.

Hannah JeffreyVP of Investor Relations

I will now turn the call over to Paul.

Paul BadawiCo-Founder and CEO

Thanks, Hannah. Good afternoon, and thank you for joining us. We are extremely proud of our results again this quarter, where we reported record revenue of $24.9 million, growing 25% year-over-year. This marks our third consecutive quarter of double-digit growth and second consecutive quarter of 20% growth or greater. IDE revenue continues to scale rapidly and reached another record quarter with revenue of $3.9 million, and IG continued its momentum and grew 7% to $21 million. Notably, we delivered this high-growth performance while both investing in our growth drivers and significantly improving our cash burn, highlighting the operating leverage in our commercial model. Based on our strong results and outlook, we are raising our full year 2026 revenue guidance while maintaining our adjusted operating expense guidance.

Paul BadawiCo-Founder and CEO

At Sight Sciences, we are focused on delivering minimally invasive technologies that address the underlying cause of two of the most common anterior segment diseases, glaucoma and dry eye disease. As the pioneer and creator of two interventional eye care categories within glaucoma and dry eye disease, Sight Sciences has taken an important leadership position in interventional eye care. To date, our products have now been used in over 500,000 procedures. As the treatment paradigm continues to shift toward earlier procedure-based care, we are well-positioned to drive expanded adoption of our technologies and improve access to earlier intervention for the patients we serve. This opportunity is particularly compelling because glaucoma and dry eye disease are increasingly seen within the same patients, practices, and treatment pathways, reinforcing our conviction that OMNI and TearCare are synergistic interventional growth drivers.

Paul BadawiCo-Founder and CEO

Within our company, we have created a third area of focus beyond IG and IDE called the Intersection of Intervention, or IX. IX is where Sight Sciences becomes more than a portfolio of products. It creates a scalable interventional eye care platform with common customers, overlapping patients, and a shared procedure-based model that can create commercial leverage across glaucoma and dry eye. At last month's American Academy of Ophthalmology's annual meeting in New Orleans, we had the privilege of celebrating the IX partners who have adopted both OMNI and TearCare into their practices and have been instrumental in leading the advancement of interventional patient care. Importantly, our established relationships in glaucoma are helping accelerate adoption of TearCare, creating a powerful connection between our two technologies. We believe this synergy represents a durable growth driver and reinforces our position as a leader in interventional eye care.

Paul BadawiCo-Founder and CEO

Now turning to our segments, beginning with IDE, where we delivered another record quarter and generated third quarter revenue of $3.9 million, an increase of 45% from the second quarter. This continued traction reflects growing TearCare adoption in the reimbursed market and further progress in building a durable, recurring procedural revenue model. Based on this momentum, we are increasing our full-year IDE revenue outlook to approximately $12 million, up from the previous range of $9 million-$11 million. Looking closer at this quarter's results, the underlying metrics of our IDE business continue to strengthen, with increases in both ordering accounts and utilization. Ordering accounts rose to 222, up from 176 in the second quarter, and those accounts purchased approximately 4,600 SmartLids, up from approximately 3,100 in the second quarter. Average utilization climbed to 21 SmartLids per ordering account, compared to 18 in the second quarter.

Paul BadawiCo-Founder and CEO

Notably, utilization increased as we added new ordering accounts, reflecting deeper adoption of TearCare across our customer base. Growth in both ordering accounts and utilization is the foundation of a durable, recurring procedural revenue model, and continued progress on both remains central to scaling our IDE business. The early adoption metrics highlight the significant opportunity ahead for the more than 7 million patients suffering from moderate to severe MGD. We continue to sharpen our go-to-market strategy as we learn from the commercial adoption of TearCare in areas with market access. We are focused on practices that already manage a high volume of dry eye patients and have embraced a procedural approach, and we are adding targeted sales and clinic support capacity to help practices quickly establish workflows and build a consistent patient flow.

Paul BadawiCo-Founder and CEO

This disciplined, focused model allows us to grow efficiently today while positioning us to scale rapidly as market access expands. Earlier in the quarter, we announced an FDA label expansion for TearCare, making it the first and only treatment for MGD indicated to improve meibomian gland function in patients suffering from dry eye disease. This updated label marks an important milestone for TearCare. While the benefits of the procedure already resonate with our customers and their patients, this label expansion recognizes TearCare's ability to improve physiological function and ultimately address the underlying cause of disease, enabling our team to strengthen the message around the benefits of the procedure for patients. Expanding equitable market access to the only reimbursed procedural intervention for the millions of patients suffering from MGD remains a top priority.

Paul BadawiCo-Founder and CEO

We continue to advance this priority through productive dialogue with multiple payers and anticipate that they will establish fee schedules and/or coverage policies in the coming quarters. To this end, we continue to invest in our team to drive the expansion of market access for TearCare through heightened engagement with MACs and commercial payers. In our conversations, we continue to highlight TearCare's robust clinical evidence, favorable health economic profile, and increasing adoption in everyday clinical practice. At the same time, we remain focused on commercially executing within the serviceable market already in front of us. We believe continued execution in these regions can drive meaningful growth, with additional positive payer decisions serving as important accelerators. Overall, IDE delivered another record quarter with growth in both ordering accounts and utilization, and an expanded FDA label that better reflects TearCare's full value.

Paul BadawiCo-Founder and CEO

Our results to date have come from a focused commercial team operating in a limited reimbursed footprint, and we believe they demonstrate the significance of this opportunity when patients have access to it. As market access expands, we believe our commercial model can scale efficiently into new regions, positioning us to pioneer and lead this category and drive significant growth in the years ahead. Moving to IG. Third quarter revenue was $21 million, an increase of 7% compared with the prior year period. This was our fifth consecutive quarter of growth, and importantly, active accounts reached another all-time high in the quarter. Based on this performance, we now expect increased full-year IG revenue of $80 million-$81 million, compared to our prior range of $79 million-$81 million.

Paul BadawiCo-Founder and CEO

Our strategic priorities remain unchanged as we continue to focus on training new surgeons, driving deeper utilization across our existing customer base, and capturing a larger share of combo cataract cases, while also continuing to activate the standalone opportunity. We were also encouraged by the expansion of OMNI and SION coverage through Aetna earlier in the quarter, adding approximately 25 million additional covered lives. Together, these efforts are strengthening our implant-free glaucoma franchise, deepening our customer relationships, and creating a solid foundation for our leading interventional eye care platform. Shortly before our last earnings call, we announced FDA 510(k) clearance of OMNI Ultra, the next-generation technology in our OMNI product line. Following an initial limited rollout, we launched Ultra commercially in the U.S. at the AAO annual meeting in New Orleans in October.

Paul BadawiCo-Founder and CEO

We are excited about the launch and believe Ultra can support sustained growth in our IG business by appealing to a broad range of surgeons and deepening engagement across our customer base. Developed with direct input from surgeon customers, Ultra includes single-pass canaloplasty, TruSync Plus for automated viscodilation, and improved catheter visualization. Early users have responded very positively to its versatility, ease of use, and meaningful improvements over the prior generation of OMNI. Ultra builds on our legacy as the pioneer of ab interno canaloplasty and demonstrates our continued commitment to innovation, further strengthening our leadership position in implant-free MIGS. In standalone, our market development work continues to focus on helping practices implement a repeatable interventional glaucoma activation workflow. This workflow was designed with the cataract workflow in mind, a familiar and effective model for practices, and is intended to help move the standalone opportunity from physician education to practical activation.

Paul BadawiCo-Founder and CEO

We believe this helps providers identify appropriate patients, integrate the procedure into clinic operations, and build more consistent adoption. The standalone market is growing, and it remains a large, under-penetrated opportunity. We believe the work we have done is beginning to contribute to growth today and is an important step toward expanding the role of interventional glaucoma in the treatment algorithm. In summary, we are proud of the performance across both of our interventional segments in the third quarter. In IDE, we are driving significant growth with a concentrated commercial team as we prepare to scale efficiently upon achieving broader market access. In IG, we are looking forward to the full launch of OMNI Ultra over the coming quarters and sustaining our growth trajectory.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day